- As the U.S. attempts to address its opioid crisis, the need for safe and effective pain management solutions is growing
- Endonovo Therapeutics is making significant progress toward commercializing its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management
- Endonovo has completed clinical trials and is currently expanding commercialization of the device
- Several strategic appointments have also been made recently to strengthen the Endonovo team and the company’s clinical work
Endonovo Therapeutics Inc. (OTCQB: ENDV) is putting a lot of effort into the commercialization of SofPulse®, the company’s Electroceutical® wearable therapeutic device for pain management. The non-invasive, safe solution delivers pulsed electromagnetic frequencies for the effective management of pain and edema after surgery.
In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe non-addictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. “The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,” Endonovo CEO Alan Collier said in a company news release (http://ibn.fm/F4JX0).
The U.S. is currently undergoing a sweeping change in chronic pain management. Nearly 70,000 people die each year in the country from drug overdoses and prescription opioid medications are often blamed for accelerating this national catastrophe, the Washington Post reports (http://ibn.fm/xzyfP).
Changes in medical guidance pertaining to the administration of opioids are now contributing to millions of patients being tapered off opioid medications. There have even been suggestions from the psychiatric community to recognize opioid dependence as a distinct condition (http://ibn.fm/PoA3J). For many patients, the therapeutic use of opioid medications lasts years, even decades. These patients develop tolerance to the drugs and end up needing much larger doses than the ones set in the 2016 CDC guidelines.
Endonovo’s goal is to provide a safe and effective, hospital-tested pain management alternative. The company’s SofPulse® is clinically proven to reduce the need for potentially addictive pain medication and help speed up the post-surgery recovery process. Endonovo’s Electroceutical Therapy® has already been cleared by the U.S. Food and Drug Administration and is CE-marked in the European Economic Area for the palliative treatment of post-surgical pain and edema.
In September 2019, the company partnered up with the Veterans Healthcare Supply Solutions (VHSS) to initiate SofPulse® sales to Veterans Health Administration and military hospitals (http://ibn.fm/u0UIg). VHSS has over 30 years of healthcare distribution management experience. It represents leading manufacturers to federal government agencies and has an already well-established portfolio of diversified products.
At the same time, Endonovo has announced two new appointments to its scientific advisory board: Dr. Samir S. Awad and Dr. Geoffrey Abrams.
Awad served as the operative line executive, chief of general surgery and medical director of the Surgical Intensive Care Unit at Michael E. DeBakey VAMC. His specialty areas include surgical oncology, abdominal wall reconstruction, acute care surgery, laparoscopic and robotic surgical procedures. “Electroceutical® therapeutic devices are a fascinating frontier of pain management, and Endonovo’s SofPulse® approaches the industry in a safe manner while fighting the opioid epidemic head on,” Awad said in a news release regarding his appointment.
Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for the Stanford varsity athletes (http://ibn.fm/QqyN8). He is actively involved in research that examines the role of inflammatory mediators on cartilage and tendon damage.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV